Andrographolide mitigates IL‑1β‑induced human nucleus pulposus cells degeneration through the TLR4/MyD88/NF‑κB signaling pathway

穿心莲内酯通过 TLR4/MyD88/NF-κB 信号通路减轻 IL-1β 诱导的人髓核细胞变性

阅读:7
作者:Lilian Zhang, Qi Chen, Haoli Wang, Jian Yang, Sunren Sheng

Abstract

Intervertebral disc degeneration (IDD) is a multifactorial disease with few efficacious clinical drugs, which has been demonstrated to be associated with nucleus pulposus (NP) cells apoptosis and degeneration of the extracellular matrix (ECM). Interleukin (IL)‑1β, a common proinflammatory cytokine, is considered to be one of key regulators in IDD development. Andrographolide (AG), extracted from Andrographis paniculata, has been suggested to possess marked anti‑inflammatory properties. However, the effects of AG on IDD has not been well explored. The present study aimed to investigate the effects and the mechanisms of AG on IDD in human NP cells. NP cells were treated with IL‑1β in the absence or presence of AG to investigate the effects on cell viability, cellular apoptosis, production of ECM and matrix metalloproteinase (MMP)‑3, MMP‑9 and MMP‑13, and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)‑4 and ADAMTS‑5. It was identified that IL‑1β‑induced NP cellular apoptosis was significantly inhibited by AG treatment. Furthermore, AG mitigated the IL‑1β‑induced degeneration of the ECM, which was paralleled by a decrease in MMPs and ADAMTS levels. In addition, AG exhibited marked inhibitory properties against the activation of Toll‑like receptors (TLRs), Myeloid differentiation factor 88 (MyD88) and the nuclear translocation of Nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF‑κB). Taken together, these results demonstrated that AG treatment mitigated IL‑1β‑induced NP cells degeneration through the TLR4/MyD88/NF‑κB signaling pathway, and suggested that AG may be a potential agent for IDD prevention and therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。